C1 Esterase Inhibitor (Cinryze)

Cinryze is covered for prophylaxis of HAE attacks and for treatment of acute HAE attacks (compendial use) only for hereditary angioedema due to C1‑INH deficiency (Type I or II); HAE with normal C1‑INH is not listed as a covered indication. Coverage requires baseline functional C1‑INH <50% and low serum C4, prescription/consultation by an allergist/immunologist or HAE specialist, adherence to age‑specific dosing limits (max 2,500 units IV q3–4 days for ≥12 years; 1,000 units IV q3–4 days for ages 6–11), and 12‑month authorization with reauthorization based on documented favorable clinical response.

"Cinryze ® is indicated for prophylaxis against Hereditary Angioedema (HAE) attacks"

Sign up to see full coverage criteria, indications, and limitations.